Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
Expert Rev Anti Infect Ther
; 13(6): 769-77, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-25865094
ABSTRACT
Carbapenem-resistant Acinetobacter baumannii (CRAB) constitutes an increasing problem worldwide. CRAB bacteremia is associated with a high fatality rate and its optimal treatment has not been established. Early institution of appropriate therapy is shown to improve survival of patients with CRAB bloodstream infection. Regrettably, treatment options are limited. Little information exists about the efficacy of sulbactam for the treatment of CRAB bacteremia. Colistin and tigecycline possess good in vitro activity and represent in many cases the only therapeutic options although clinical data are scarce. The need for a loading dose of colistin has been recently demonstrated to rapidly achieve therapeutic levels. The use of combination therapy is also a matter of debate but current evidence do not support its routine use.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por Acinetobacter
/
Carbapenêmicos
/
Bacteriemia
/
Resistência beta-Lactâmica
/
Acinetobacter baumannii
/
Antibacterianos
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article